At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Apr 9, 2026 at 07:01 ET
Invivyd announced progress in its Phase 3 DECLARATION study for VYD2311, including a pre-specified upsizing by ~500 subjects to ensure robust statistical power, pushing top-line results to Q3 2026. The company also announced the advancement of VMS063, a novel measles monoclonal antibody candidate, with IND readiness targeted for late 2026.
- DECLARATION Phase 3 study upsized by ~500 subjects, increasing total enrollment beyond initial 1,818.
- Top-line results for VYD2311 now expected in Q3 2026, a two-month delay from prior 'mid-year' guidance.
- FDA alignment on initial Pediatric Study Plan (DRUMMER trial) for VYD2311 in children aged 0-11, contingent on adult trial success.
- VMS063, a novel measles mAb candidate, advanced toward IND-enabling studies with target IND readiness in late 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access